IgA Nephropathy clinical trials at University of California Health
2 in progress, 1 open to eligible people
Showing trials for
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.
at UCLA
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Sorry, in progress, not accepting new patients
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
at UCLA
Last updated: